SEC Form 4

 \Box

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

Estimated average bur	den
hours per response:	0.5
L	
olationship of Reporting Porson(s) to I	cellor

1. Name and Address of Reporting Person			2. Issuer Name and Ticker or Trading Symbol PHARMATHENE, INC [PIP]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>GILL JOHN</u>			L =]	X	Director	10% Owner			
(Last) (First) (Middle) C/O PHARMATHENE, INC		(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/22/2012		Officer (give title below)	Other (specify below)			
ONE PARK PLACE, SUITE 450				6. Individual or Joint/Group Filing (Check Applicable					
	ICE, SUITE 450		4. If Amendment, Date of Original Filed (Month/Day/Year)		dual or Joint/Group Filing	(Check Applicable			
(Street) ANNAPOLIS	MD	21401	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	dual or Joint/Group Filing Form filed by One Repor Form filed by More than Person	ting Person			

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (3. 4. Securities Acquired (A) or Transaction Disposed Of (D) (Instr. 3, 4 and Code (Instr. 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	3, 4 and (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock option (right to buy)	\$1.45	06/22/2012		A		20,000		06/22/2013	06/22/2022	Common Stock	20,000	(1)	20,000	D	

Explanation of Responses:

1. On June 22, 2012, the date the stock option was granted, the closing price of the Issuer's common stock was \$1.45 per share.

/s/ Roland S. Chase, attorney in fact 06/26/2012

fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.